The most common recombinant antibody format is the single chain fragment variable (scFv)
which it contains the complete antigen-binding domains of an intact antibody. ScFv …

Antibodies and antibody-based drugs are currently the fastest-growing class of therapeutics.
Over the last three decades, more than 30 therapeutic monoclonal antibodies and …

Background The connection of the variable part of the heavy chain (VH) and and the
variable part of the light chain (VL) by a peptide linker to form a consecutive polypeptide …

Recombinant antibodies are rapidly developing therapeutic agents; approximately 40 novel
antibody molecules enter clinical trials each year, most of which are produced from Chinese …

Background The demand of monospecific high affinity binding reagents, particularly
monoclonal antibodies, has been steadily increasing over the last years. Enhanced …

Phage display antibody libraries have proven an invaluable resource for the isolation of
diagnostic and potentially therapeutic antibodies, the latter usually being antibody fragments …

Antibody-based proteins have become an important class of biologic therapeutics, due in
large part to the stability, specificity, and adaptability of the antibody framework. Indeed …

▪ Abstract Antibodies are unique in their high affinity and specificity for a binding partner, a
quality that has made them one of the most useful molecules for biotechnology and …

Single-chain variable antibody fragments (scFvs) are attractive candidates for targeted
immunotherapy in several human diseases. In this study, a concise humanization strategy …

Antibody drugs have been used to treat a number of diseases successfully. Producing
antibodies with high yield and quality is necessary for clinical applications of antibodies. For …